|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02348 DAWNRAYS PHARMA
Nominal 
1.160 +0.010 (+0.870%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 1,060,309 | -7.891% | 1,151,145 | 1,277,682 | 1,165,155 | 1,024,270 |
| Cost of Sales | (482,681) | -5.287% | (509,626) | (504,131) | (483,893) | (473,625) |
| Gross Profit | 577,628 | -9.959% | 641,519 | 773,551 | 681,262 | 550,645 |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (3,696) | -90.971% | (40,933) | (61,905) | (46,418) | (18,771) | |
| Profit / (Loss) before Taxation | 636,949 | 53.831% | 414,057 | 438,408 | 439,323 | 331,298 | |
| Taxation | (74,187) | -18.824% | (91,390) | (82,557) | (85,160) | (66,505) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 2,178 | -34.653% | 3,333 | 2,206 | 4,012 | 3,337 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 564,940 | 73.294% | 326,000 | 358,057 | 358,175 | 268,130 | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (32,815) | 31.586% | (24,938) | (19,004) | (19,171) | (12,250) |
| Depreciation & Amortisation | 106,623 | 27.094% | 83,893 | 66,410 | 57,545 | 56,008 |
| Directors' Emoluments | -- | -- | 2,973 | 3,089 | 9,667 | 10,861 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 37.540 | 72.677% | 21.740 | 23.890 | 23.920 | 17.360 |
| DPS (cts) | 8.798 | -- | 7.262 | 7.666 | 6.513 | 9.702 |
| Dividend Payout Ratio (%) | 23.437% | -- | 33.405% | 32.087% | 27.226% | 55.888% |
| Cash flow per share ($) | -- | -- | 0.226 | 0.290 | 0.263 | 0.196 |
| NBV per share ($) | 2.213 | -- | 1.903 | 1.763 | 1.589 | 1.433 |
| Remarks: | Real time quote last updated: 23/04/2025 15:10 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 564,940 |
| %Change | 73.294% |
| EPS / (LPS) | RMB 0.375 |
| NBV Per Share (¥) | RMB 2.213 |